Kineta, Inc. (OTC Pink: KANT) announced that its abstract regarding the KVA12123 clinical program has been accepted for a poster presentation at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting, scheduled to take place from November 6-10, 2024, in Houston, Texas.
Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, confirmed that Dr. Jason Henry, Associate Director, Drug Development at Sarah Cannon Research Institute, Denver Colorado, will present the poster on November 8, 2024. The presentation will feature new clinical data from an ongoing Phase 1/2 clinical trial evaluating KVA12123, Kineta’s VISTA blocking immunotherapy, both as a monotherapy and in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with advanced solid tumors.
Presentation Details
- Title: A phase 1/2 clinical trial of antiVISTA – KVA12123 alone and in combination with pembrolizumab in patients with advanced solid tumors
- Abstract Number: 625
- Date / Time: Friday, November 8 at 9:00 A.M. – 7:00 P.M. Central Time
- Location: Exhibit Halls AB – George R. Brown Convention Center, Houston, Texas
The abstract titles are currently accessible on the SITC website. Following the presentation at the conference, the posters will be available on the Kineta website.
About KVA12123
KVA12123 is designed to counteract immune suppression within the tumor microenvironment. Preclinical models have demonstrated that KVA12123 exhibits significant tumor growth inhibition, both as a standalone treatment and when combined with other checkpoint inhibitors. Kineta believes KVA12123 may be a beneficial immunotherapy for various cancer types, including non-small cell lung cancer (NSCLC), colorectal cancer, renal cell carcinoma, head and neck cancer, and ovarian cancer.
Kineta's Strategic Focus
Kineta is a clinical-stage biotechnology company focused on developing immunotherapies. The company's pipeline includes KVA12123 and a preclinical monoclonal antibody targeting CD27. In February 2024, Kineta underwent a corporate restructuring to reduce expenses, which included a workforce reduction and suspension of new patient enrollment in the VISTA-101 Phase 1/2 clinical trial. The company is also exploring strategic alternatives to maximize stockholder value.
